Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating ...

On Tuesday, Johnson & Johnson (JNJ) stock saw a decline, ending the day at $152.64 which represents a decrease of $-2.40 or -1.55% from the prior close of $155.04. The stock opened at $154.53 and ...

Looking for the latest stock opportunities in December 2024? We have you covered. Click to read our top stock picks to ...

HRSA’s threats of penalties led J&J to halt the plan, prompting a legal battle to protect its proposed changes. Johnson & ...

Historically an active player in the M&A space, Radnor-based Avantor has not found itself so busy in that realm during the ...

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

The stock is currently at ~$190. There was a ~10% further increase over the last two quarters. Johnson & Johnson (JNJ): JNJ ...

Johnson & Johnson (NYSE:JNJ) saw a reduction of 1,734,184 shares, resulting in a -54.12% reduction in shares and a -1.33% ...

The firm’s lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy is for the treatment of multiple myeloma. Its other pipeline products include LB1910, ...

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Legend Biotech (LEGN – Research Report) and keeping the price ...

Angela Meady lives in Thunder Bay, Ontario where many Slovak people settled from the 1880s through 1950s. Angela has degrees in English Literature, Philosophy and Information Science and is director ...

Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.